Amgen Inc. buy melinda
Start price
24.03.18
/
50%
€155.86
Target price
04.06.18
€166.87
Performance (%)
8.04%
End price
04.06.18
€167.19
Summary
This prediction ended on 04.06.18 with a price of €167.19. The BUY prediction by melinda finished with a performance of 8.04%. melinda has a follow-up prediction for Amgen Inc. where he still thinks Amgen Inc. is a Buy. melinda has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| Amgen Inc. | -1.652% | -1.652% | 8.331% | 52.003% |
| iShares Core DAX® | -3.520% | -4.987% | 1.926% | 50.820% |
| iShares Nasdaq 100 | 0.261% | 1.102% | 15.434% | 90.843% |
| iShares Nikkei 225® | -4.953% | -3.352% | 29.010% | 51.211% |
| iShares S&P 500 | -0.823% | -0.042% | 10.814% | 62.945% |
Comments by melinda for this prediction
In the thread Amgen Inc. diskutieren
SectorDrug Pharmaceuticals Agenda 24/04 Veröffentlichung der Ergebnisse
Amgen erhält positive CHMP-Stellungnahme Anerkennung von Repatha® (Evolocumab) verhindert Herzinfarkt und Schlaganfall Gepostet um 07:44 EST
Amgen (NASDAQ: AMGN) gab heute bekannt, dass der Ausschuss für Humanarzneimittel (CHMP) der Europäischen Arzneimittel-Agentur (EMA) eine positive Stellungnahme angenommen hat, um eine neue Indikation in Repatha® aufzunehmen